5:32 PM
 | 
Jun 19, 2008
 |  BC Extra  |  Clinical News

Forest's ceftaroline meets cSSSI endpoint

Forest (NYSE:FRX) said ceftaroline met the primary endpoint of a clinical cure rate that was non-inferior to vancomycin plus aztreonam in the Phase III CANVAS I and CANVAS II trials to...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >